Amsbio offers a wide selection of over 325,000 pre-characterized chemical compounds to support your drug screening applications for discovery and development.
From individual inhibitors, agonists and natural products to ready-to-screen compound libraries, these cost-effective, high-quality reagents are perfect for both academic and industrial research.
Whether you are studying apoptosis, autophagy, cell cycle regulation, immunology, or signaling cascades our portfolio of over 20,000 small molecule inhibitors and agonists offer excellent membrane permeability…
The global collaboration provides an integrated translational biology platform to accelerate the development of novel radiopharmaceuticals.
Medicines Discovery Catapult (MDC) and Crown Bioscience have formed a strategic global collaboration to deliver an integrated translational biology platform for innovators developing radiopharmaceuticals.
Radiopharmaceuticals are a growing class of medicines that contain radioactive forms of chemical elements (called radioisotopes) that effectively diagnose and treat cancers. They provide a rapidly advancing approach to the future of medical research and…
Sandwich, UK and Illkirch-Graffenstaden, France (10 September 2025) – Logical Biological, biospecimen and critical raw material leader based at Discovery Park, and Bcell Design, pioneers in transgenic monoclonal antibody technology, today announced a long term strategic international partnership to deliver engineered disease state materials for diagnostic and research markets.
Working together, the two companies will develop customised engineered disease state and ‘spiking’ materials to deliver compelling alternatives to native disease state plasma. Materials are designed and formulated to…
Giants of the Science and Biotechnology World Gather for a Unique Conference
• Conference is between 17th and 19th September• https://conferences.biocentury.com/grand-rounds-europe
Hundreds of global academic innovators, pharmaceutical industry leaders, emerging biotechnology companies and life science investors are converging on Cambridge this week for the inaugural BioCentury Grand Rounds Europe conference – a prestigious event bringing together some of the world’s best scientists in a bid to tackle some of the most stubborn problems in medical science. This is the first time…
CPI and Quotient Sciences have signed a memorandum of understanding (MoU) to form a Joint Venture (JV) aimed at accelerating the development of RNA-based therapies. The JV will combine Quotient Sciences’ Translational Pharmaceutics® platform with CPI’s expertise in small-scale manufacture of RNA and LNP encapsulation to deliver a first-of-its-kind, integrated offering for the development of mRNA drug products. The JV will address the growing industry demand for agile solutions that bring new RNA therapeutics…
Sandwich, UK - 10 September 2025: Discovery Park, Kent’s thriving life science and innovation community, today welcomed eight promising cardiovascular and cardiometabolic health startups to its campus. The cohort are embarking on the ‘Discovery Spark’ business growth programme, championing and supporting early stage business working on innovations in heart health.
The early stage companies were selected from a wide pool based on the need for their innovation, the uniqueness of their solution, and the strength of their team. Over the next six weeks, the companies will attend expert-led…
LONDON, September 10, 2025 – Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, successfully completed a search assignment for the Cell and Gene Therapy Catapult (CGT Catapult) and is pleased to announce the placement of Dr. Ed Samuel as Chief Operations Officer (COO).CGT Catapult is an independent technology and innovation organization specializing in the advancement of the cell and gene therapy industry through powerful collaborations.Ed Samuel has over 20 years of experience in advanced therapies, including…
Recently, Medicilon officially obtained the Good Laboratory Practice (GLP) certification certificate issued by Mexico, a member country of the OECD. In addition, we successfully passed GLP on-site inspections conducted by Hungary.
Following recent FDA and PMDA GLP audits, this achievement reaffirms that Medicilon’s preclinical research quality continues to meet the highest international standards.
🌍 Committed to Compliance Management, Empowering Global Drug Innovation
OECD GLP certification is recognized globally as the gold standard in preclinical safety evaluation for its rigor,…
Creative Biolabs delivers customized preparation solutions to solve the tough challenges facing membrane protein discovery, ensuring to yield proteins that remain functional and ready for downstream applications. Researchers have been fascinated by membrane proteins for years: A 2016 paper in Nature Methods shed light on the stubborn technical barriers of isolating these proteins in their native form, and more recently, in 2023, a PNAS study demonstrated how advanced protocols can unravel structural details.Yet the cruel reality is that not that many labs hold the techniques for…
London, UK, 8 September 2025 – Myricx Bio (‘Myricx’), a UK-based biotech company focusing on the discovery and development of a completely novel class of payloads for antibody-drug conjugates (ADCs), is pleased to announce the appointment of Jonathon Marks-Bluth, Ph.D., to its leadership team in the newly created position of VP, Business Development.
Based at Myricx’s London, UK facilities, Jonathon joins the company at a time when its multiple N-myristoyltransferase inhibitor (NMTi)-ADC programs are advancing towards clinical development and where partnership options are being explored.…